Skip to main content

Advertisement

Table 3 Comparison of plasma miRNA levels in patients with cervical lesions of different grades

From: Plasma expression of miRNA-21, − 214, −34a, and -200a in patients with persistent HPV infection and cervical lesions

Area group(2-CT, x ± s)
normal controls persistent hr-HPV CIN1 CIN1- CIN2 CIN3 cancer CIN2+
Number of cases 42 31 19 92 54 71 15 140
miRNA-21 1.96 ± 3.08 1.69 ± 2.72 3.79 ± 6.17 2.25 ± 3.93 6.88 ± 11.25 5.37 ± 6.25 6.87 ± 12.99 6.12 ± 9.37
miRNA-214 1.68 ± 3.40 2.20 ± 3.38 0.63 ± 1.79 1.63 ± 3.20 0.31 ± 1.29 0.30 ± 1.28 0.23 ± 0.31 0.29 ± 1.22
miRNA-200a 0.47 ± 0.62 0.78 ± 0.96 0.21 ± 0.35 0.52 ± 0.74 0.24 ± 0.41 0.22 ± 0.27 0.18 ± 0.19 0.22 ± 0.32
miRNA-34a 1.62 ± 2.64 2.24 ± 2.94 0.72 ± 1.39 1.64 ± 2.62 0.77 ± 1.34 0.78 ± 1.78 0.45 ± 0.27 0.74 ± 1.53
  1. In Table 3, 42 normal controls, 31 persistent HPV patients and 19 CIN1 patients were combined to obtain 92 CIN1- subjects, and 54 CIN2, 71 CIN3 and 15 cancer patients were combined for a total of 140 patients in the CIN2+ group
  2. Plasma miRNA levels in the CIN1- group were significantly different from those in the CIN2+ group, p < 0.01 (miRNA21, t = 4.34, p = 0.000; miRNA214, t = 4.18, p = 0.0001; miRNA200a, t = 3.67, p = 0.0002; miRNA, t = 2.98, p = 0.0017)